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Abstract
Docetaxel is currently the most effective drug for the treatment of castration-resistant prostate cancer (CRPC), but
it only extends life by an average of 2 months. Lycopene, an antioxidant phytochemical, has antitumor activity
against prostate cancer (PCa) in several models and is generally safe. We present data on the interaction between
docetaxel and lycopene in CRPC models. The growth-inhibitory effect of lycopene on PCa cell lines was positively
associated with insulin-like growth factor I receptor (IGF-IR) levels. In addition, lycopene treatment enhanced the
growth-inhibitory effect of docetaxel more effectively on DU145 cells with IGF-IR high expression than on those PCa
cell lines with IGF-IR low expression. In a DU145 xenograft tumor model, docetaxel plus lycopene caused tumor
regression, with a 38% increase in antitumor efficacy (P = .047) when compared with docetaxel alone. Lycopene
inhibited IGF-IR activation through inhibiting IGF-I stimulation and by increasing the expression and secretion of
IGF-BP3. Downstream effects include inhibition of AKT kinase activity and survivin expression, followed by apoptosis.
Together, the enhancement of docetaxel’s antitumor efficacy by lycopene supplementation justifies further clinical
investigation of lycopene and docetaxel combination for CRPC patients. CRPC patients with IGF-IR–overexpressing
tumors may be most likely to benefit from this combination.
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Introduction
Most advanced prostate cancer (PCa) patients respond well to initial
treatment with androgen-deprivation therapy (ADT) [1,2]. However,
nearly all patients eventually develop resistance to ADT and disease
progression [1,2]. Docetaxel-based chemotherapy has recently shown
significant but short-lived survival benefit and has become the major
remaining treatment option for castration-resistant PCa (CRPC) [3].
However, with the demonstrated survival benefit of approximately
2 months, median survival of 18 to 20 months and a response rate of
only approximately 50%, the docetaxel-based chemotherapy remains
palliative for men with CRPC. Therefore, there is a need for investiga-
tion and development of novel agents that can add to and improve the
docetaxel-based therapy.
PCa is a biologically complex and highly heterogeneous disease [4–6].
The complex interactions of nutrients with genetic and hormonal effec-
tors not only contribute to the development of distinct clinical pictures
of PCa among different geographical regions [4–6] but also make PCa
an especially amenable target for preventive and therapeutic interven-
tion through nutritional combinations. Lycopene is a plant carotenoid
naturally present in tomatoes and tomato products [7]. Lycopene
accumulates in prostate tissue and functions as a potent antioxidant in
in vitro systems [7–10]. In a large prospective cohort study, Giovannucci
et al. [11] reported that consumption of lycopene-rich foods was asso-
ciated with a 30% to 40% reduction in the PCa risk and that the pre-
ventive effects of lycopene-rich foods aremore pronounced in subgroups
with aggressive disease, older men, or men without a family history of
PCa. Moreover, lycopene was shown to inhibit both IL-6 signaling and
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the IGF-I pathways that participate in resistance to ADT and chemo-
therapy (e.g., docetaxel) [12–20]. Therefore, lycopene could be an
attractive agent in augmenting docetaxel-based chemotherapy for treat-
ment of men with CRPC.
Alternatively, lycopene could potentially function as a potent anti-
oxidant in PCa per se to inhibit oxidative stresses and DNA damage
[21–24], antagonizing the therapeutic effects of docetaxel [21]. De-
spite the recommendations from oncology societies not to take supple-
ments during chemotherapy [21], many patients do mix conventional
and alternative treatments. Therefore, there is an urgent clinical need
to address whether the concurrent use of lycopene supplements with
docetaxel-based chemotherapy would antagonize or enhance anti-
tumor efficacy.
In this study, we demonstrate that lycopene enhances the effect of
docetaxel on the growth of CRPC cell lines both in vitro and in vivo.
PCa cell lines expressing high insulin-like growth factor I receptor
(IGF-IR) levels are more sensitive to the growth-inhibitory effect of
lycopene compared with those cell lines with low IGF-IR. Our data
suggest that one potential mechanism of lycopene’s action is inac-
tivation of IGF-IR by inhibiting IGF-I stimulation and by increasing
the expression and secretion of IGF-BP3. Downstream effects include
inhibition of AKT kinase activity and survivin expression, followed
by apoptosis.
Materials and Methods
Cell Lines, Plasmid, Stable Transfection,
Compounds, and Reagents
The LNCaP, LAPC-4, DU145, 22Rv1, and PC-3 cell lines were
obtained from ATCC (Manassas, VA) and cultured in RPMI 1640
medium with 10% FBS.
The PCDNA3.1, containing a full-length 4.7-kb fragment of IGF-IR,
was described previously in detail [25]. LNCaP cells were stably trans-
fected with pcDNA3.1(+)/IGF-IR using FuGENE 6 (Roche, Indiana-
polis, IN). Transfected cells were selected with G418 (800 μg/ml)
starting at 48 hours after transfection, and all of the stable transfectants
were pooled to avoid cloning artifacts. Pooled stable clones of LNCaP
cells expressing IGF-IR were maintained in RPMI containing 10% FBS
and 500 μg/ml G418.
Tetrahydrofuran (THF) containing 0.025% butylated hydroxy-
toluene was purchased from Sigma (St Louis, MO). Pure all-trans
lycopene was purchased from Wako Chemicals, Inc (Irvine, CA)
and dissolved in THF to a concentration of 15 mM. This stock solu-
tion was prepared with minimal exposure to air and light and stored at
−80°C. LycoVit 10% cold water dispersible (CWD) was from BASF
Corporation (Shreveport, LA), which contains microencapsulated
synthetic lycopene. There is 11.45% total lycopene with 77% all-
trans and 23% total cis-lycopene, and less than 2% vitamin E in this
product. Docetaxel injection solution was obtained from the UCI
Medical Center Pharmacy. Picropodophyllin (PPP), a potent and se-
lective IGF-IR kinase inhibitor, was purchased from Biaffin GmbH&
CoKG (Kassel, Germany). Thymidine, 3-(4, 5-dimethylthiazol-2-yl)-2,
5-diphenyltetrazolium bromide (MTT), propidium iodide (PI), and
other chemicals were from Sigma.
Antibodies for AKT, phospho-AKT, and survivin were from Cell Sig-
naling Technology, Inc (Beverly, MA). Antibodies against IGF-IRβ
and β-actin were from Santa Cruz Biotechnology (Santa Cruz, CA).
IGF-BP3 antibody was purchased from Upstate Biotechnology (Lake
Placid, NY). Ki67 antibody was from Novus Biologicals (Littleton,
CO). DeadEnd Colorimetric Terminal Deoxynucleotidyl Transferase
dUTP Nick End Labeling (TUNEL) System was from Promega
(Madison, WI).
MTT Assay
The MTTassay was performed as previously described [26]. Dose-
response curves for growth inhibition were generated as a percentage
of vehicle-treated control. Immediately before the experiment, THF-
lycopene aliquots from the stock solution were added to culture me-
dium to achieve a final concentration of 0.05, 0.5, 1, 5, 10, 50, and
100 μM. The final maximum concentration of THF in the culture
medium was 0.1%, which did not affect cell viability as indicated by
comparison with control medium. PPP was dissolved in ethanol and
added to the culture medium to achieve a final concentration of 7.8,
15.6, 31.25, 62.5, 125, 250, and 500 nM. Cells were treated for 3 days.
MTTwas added to a final concentration of 1 mg/ml. The reaction mix-
ture was incubated for 3 hours at 37°C, and the absorbance was mea-
sured at 570 nm.
DNA Histogram Analysis
Cells were treated with vehicle controls (0.1% DMSO, 0.1% THF,
or 0.1% DMSO + 0.1% THF), 1 μM lycopene, 10 μM lycopene,
1 nM docetaxel, 31.25 nM PPP, 1 or 10 μM lycopene plus 1 nM
docetaxel, or 31.25 nM PPP plus 1 nM docetaxel for 24 hours. After
the stated treatments, cells were stained with PI in PBS. All analyses of
cells were done using appropriate scatter gates to exclude cellular debris
and aggregated cells. Ten thousand events were collected for each sam-
ple stained PI.
Western Blot Analysis and Immunoprecipitation
Clarified protein lysates (20-80 μg) were denatured and resolved
by 8% to 16% SDS-PAGE. Proteins were transferred to nitrocellulose
membranes, probed with antibodies, and visualized by an enhanced
chemiluminescence detection system.
Total protein (500 μg) was precleared with protein A-agarose and
then precipitated with 2 μg of anti–IGF-IRβ or IgG antibody over-
night at 4°C. Agarose beads were washed four times with lysis buffer
and resuspended in SDS-PAGE 2× sample buffer. Proteins were eluted
by boiling the beads and subjected to immunoblot analysis of anti-
phosphotyrosine or anti–IGF-IRβ.
In Vivo Tumor Model
NCR-nu/nu (nude) mice were obtained from Taconic Farms
(Germantown, NY). DU145 cells were concentrated to 1 × 106 per
100 μl of PBS and injected subcutaneously into the right flank of each
mouse. Once xenografts started growing, their sizes were measured
twice a week. The tumor volume was calculated by the formula:
0.5236L1(L2)
2, where L1 is the long axis and L2 is the short axis of
the tumor. Once mice bearing the DU145 tumors (eight per group)
developed a tumor size of approximately 200 mm3, they were randomly
assigned to four different treatment groups including vehicle control
(water), 15 mg/kg LycoVit 10% CWD daily, 10 mg/kg docetaxel
weekly for three doses, and 15 mg/kg lycopene daily plus three weekly
doses of docetaxel. Lycopene was given as LycoVit 10% CWD sus-
pended in cold water by gavage. Docetaxel was given by intraperitoneal
injection. At the end of the experiment, tumors were excised and
weighed, blood was collected, and all were stored at −80°C until addi-
tional analysis.
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To assess if these treatments affected survival or tumor growth delay
of mice bearing DU145 tumors, these mice were administered vehi-
cle control (water), lycopene (15 mg/kg per day) alone, docetaxel (5 or
10 mg/kg per week for three doses) alone or combination of both and
followed up until the tumor volume reached 1500 mm3. All mice that
died prematurely or were killed had necropsy done on them to ensure
that there were no pathologic disease other than tumor-related disease.
Immunohistochemical Staining for Ki67 and Survivin
Tumor tissues were harvested and fixed in 10% phosphate-buffered
formalin, paraffin-embedded, and sectioned. Antigen retrieval was
done using 10 mM sodium citrate (pH 6.0) at 95°C for 15 minutes.
Sections were incubated with mouse monoclonal anti-Ki67 antibody
(1:500 dilution) or antisurvivin (1:50) in PBS for 2 hours at room tem-
perature in a humidity chamber followed by overnight incubation at
4°C. Slides were then incubated with a biotinylated secondary anti-
body. Slides were counterstained with Harris hematoxylin and photo-
graphed using a light microscope. Negative control samples were
exposed to a secondary antibody with a similar IgG isotype to the pri-
mary antibody. Proliferating cells were quantified by counting Ki67-
positive cells (brown stained) and total number of cells at five arbitrarily
selected fields at ×400 magnification.
TUNEL Staining for Apoptotic Cells
Apoptotic cells were detected using the DeadEnd Colorimetric
TUNEL system following the manufacturer’s protocol. The extent
of apoptosis was evaluated by counting the TUNEL-positive cells
(brown-stained) as well as the total number of cells in five randomly
selected fields at ×400 magnification.
Statistics
Comparisons of cell cycle population, proliferation and apoptosis
indices, cell viability between treatment and control were conducted
using Student t test or one-way ANOVA followed by Bonferroni t test.
For tumor growth experiments, repeated-measures ANOVA was used
to examine the differences in tumor sizes among treatments, time
points, and treatment-time interactions. Additional posttests were
done to examine the differences in tumor sizes between control and
treatments at each time point by using conservative Bonferroni method.
To correlate cell growth-inhibitory effect of levels and IGF-IR protein
expression on Western blots, Pearson correlation coefficient was calcu-
lated from their IC50 values and from densitometry measurements of
protein bands. Log-rank test was used to analyze the survival of tumor-
bearing mice between control and treatment groups. All statistical tests
were two-sided. P < .05 was considered statistically significant.
Results
Lycopene Enhances the Growth-Inhibitory Effect of Docetaxel
on PCa Cell Lines
To examine whether lycopene can interfere with or enhance the
anti-PCa activity of docetaxel, we have treated 22Rv1, LNCaP,
LAPC-4, DU145, and PC-3 cells with 1 nMdocetaxel, 1μM lycopene
(a pharmacologically achievable concentration) [7], or combination of
both for 3 days. One nanomolar of docetaxel inhibited the cell growth
of 22Rv1, LNCaP, LAPC-4, PC-3, and DU145 by approximately
54%, 35%, 19%, 27%, and 0%, respectively, whereas 1 μM lycopene
reduced their growth by 10% (22Rv1), 5% (LNCaP), 19% (LAPC-4),
0% (PC-3), and 24% (DU145) (Figure 1A). When these cells were
treated with the combination of docetaxel and lycopene, the cell den-
sities of DU145, PC-3, 22Rv1, LNCaP, and LAPC-4 were further re-
duced by 78%, 21%, 20%, 21%, and 0%, respectively, compared with
docetaxel alone (Figure 1A). The growth-inhibitory effect of the com-
bination on DU145, PC-3, 22Rv1, and LNCaP cells was greater than
the effects of docetaxel treatment alone (ANOVA test, P values < .05;
Figure 1A). Notably, the growth-inhibitory effect of the combination
on DU145 cells with higher IGF-IR expression is the most pro-
nounced among the tested cell lines. These results suggest a synergistic
and/or additive effect of docetaxel and lycopene on cell growth de-
pending on cell types.
Cell cycle analysis further revealed that lycopene and docetaxel
combination resulted in a significant increase in the pre-G1 population
of DU145 cells compared with either lycopene or docetaxel treatment
alone (Figure 1, B and C ; P values < .05, ANOVA test). This result
suggests that lycopene may increase DU145 cell sensitivity to docetaxel-
mediated apoptosis. Its effects in other cell lines were less marked (data
not shown).
The Inhibitory Effect of Lycopene on the Growth of PCa
Cell Lines Is Associated with the Levels of IGF-IR
Figure 2A show that DU145 cells with higher levels of IGF-IR were
approximately three- to seven-fold more sensitive to the inhibitory
effect of lycopene on cell viability than other tested cell lines. Table 1
shows that the IC50 values of lycopene for DU145, PC-3, LNCaP,
22Rv1, and LAPC-4 cells were estimated to be 5.1, 15, 36 16, and
50 μM, respectively, and their levels of IGF-IR (Figure 2B) were esti-
mated by densitometry to be 9.3 (DU145), 4.1 (PC-3), 2.0 (LNCaP),
1.0 (22Rv1), and 0.8 (LAPC-4), respectively. There was a trend that
cell lines with more IGF-IR expression are more sensitive to lyco-
pene treatment (Pearson correlation coefficient, −0.58; Student t test,
P values < .05). However, in addition to difference in IGF-IR levels,
these cell lines have other distinct characteristics (e.g., androgen re-
ceptor, p53, and PTEN status) that may influence their response to
lycopene or docetaxel [27]. To avoid these confounding factors, we
established a pair of isogenic cell lines: parental LNCaP and LNCaP
stably expressing high levels of IGF-IR (LNCaP/IGF-IR) (Figure 2C).
Figure 2D shows that LNCaP/IGF-IR cells were approximately 400-fold
more sensitive to the effect of lycopene on reduction of cell viability than
parental LNCaP cells (IC50 values for LNCaPand LNCaP/IGF-IRwere
36 and 0.08 μM, respectively). This result suggests that IGF-IR may
be a critical factor for the growth-inhibitory effect of lycopene.
PPP, a Selective IGF-IR Kinase Inhibitor, Also Potentiates
the Growth-Inhibitory Effect of Docetaxel on DU145 and
LNCaP Overexpressing IGF-IR Cell Lines
We next examine whether IGF-IR expression was related to the
effectiveness of PPP, a selective IGF-IR kinase inhibitor, on PCa cell
growth, and whether PPP could enhance the efficacy of docetaxel on
PCa cell growth. Figure 3A shows that LNCaP overexpressing IGF-IR
were approximately seven-fold times more sensitive to PPP treatment
for its growth-inhibitory effect than the parental LNCaP cell line. This
result suggested that inhibition of IGF-IR activation by an IGF-IR
kinase inhibitor also, at least in part, required IGF-IR expression for
its capacity to reduce PCa cell growth.
Figure 3B shows that 31.25 nM PPP in combination with 1 nM
docetaxel for the treatment of DU145 and LNCaP/IGF-IR cell lines
increased the absolute reduction of cell growth by approximately
65% to 58%, respectively, compared with docetaxel treatment alone
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Figure 1. Lycopene enhances the effect of docetaxel on reduction of cell viabilities and induction of apoptosis. (A) A total of 5× 104 22Rv1,
LNCaP, LAPC-4, DU145, and PC-3 cellswere plated in 24-well culture plates. After 24 hours, themediumwas changed to freshmediumand
treated with vehicle controls (0.1% DMSO alone, 0.1% THF alone, or 0.1% DMSO plus 0.1% THF), 1 nM docetaxel (blank bars), 1 μM
lycopene (strip bars), and 1 nM docetaxel plus 1 μM lycopene (solid bars). The medium was changed daily, after 72 hours of treatments;
the number of viable cells was measured by the MTT assay and expressed relative to their vehicle controls. Each point is the mean of four
independent plates. Bars, ±SE. (B and C) DU145 cells were stained by PI and pre-G1, and the cell cycle populations were analyzed by flow
cytometry. Con, Lyco1, Lyco10, and Doc1 denote vehicle control, 1 μM lycopene, 10 μM lycopene, and 1 nM docetaxel, respectively. A
representative photograph of cell cycle population distribution for each treatment is presented. Each bar represents the mean ± SE from
three independent experiments.
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(P values < .01, Student t test). Furthermore, cell cycle analysis of
pre-G1 population showed that lycopene significantly potentiated the
apoptotic effect of docetaxel in DU145 cells (Figure 3,C andD). These
results confirm that inhibition of IGF-IR activity can enhance the anti-
PCa activities of docetaxel.
Lycopene Inhibits IGF-I–Induced IGF-IR Activation and
Increases IGF-BP3 Expression and Secretion, Leading to
Inhibition of Downstream Signaling Events
Because the inhibitory effect of lycopene on the growth of PCa cell
lines is associated with cellular IGF-IR levels, we examined whether
lycopene inhibited IGF-I–induced IGF-IR activation. Figure 4A
(panels a and b) shows that pretreatment of serum-starvedDU145 cells
with lycopene or PPP for 2 hours attenuated IGF-I–induced IGF-IR
phosphorylation without changing IGF-IR protein levels, suggesting
that lycopene may directly interfere with IGF-I activation of IGF-IR
or IGF-IR kinase activity. In addition, Figure 4A (panels c and d ) shows
that treatment of DU145 cells with lycopene for 24 hours resulted in a
dose-dependent increase of IGF-BP3 protein expression and secretion.
The increased IGF-BP3 levels seen after lycopene treatment are also
expected to block IGF-I activation of IGF-IR through autocrine and
paracrine mechanisms.
Figure 4A (panels e and f ) shows that lycopene treatment caused
a dose-dependent decrease of active AKT (as indicated by its phos-
phorylation) without affecting total AKT protein levels. The inhibitory
effect of lycopene on AKTactivation is more pronounced inDU145 than
in LNCaP cells. Compared with DU145 cells, LNCaP cell line has a
higher level of AKT phosporylation owing to its loss of PTEN [25],
although it expresses less IGF-IR. It is possible that the downstream
Table 1. The Relationship between IGF-IR Levels and the IC50 Values of Lycopene in PCa Cell Lines.
LNCaP/IGF-IR DU145 PC-3 LNCaP 22RV1 LAPC-4
IC50 values of lycopene 0.08 5.1 15 36 16 50
IGF-IR levels estimated 77.19 9.3 4.1 2.0 1.0 0.8
Figure 2. The inhibitory effect of lycopene on the viability of PCa cell lines is dependent on their IGF-IR levels. (A) A total of 5 × 104 22Rv1,
LNCaP, LAPC-4, DU145, and PC-3 cells were plated in 24-well plates. After 24 hours, the medium was changed to fresh medium and
treated with vehicle control (0.1% THF) and different concentrations of lycopene (1-100 μM). The medium was changed daily. After
72 hours of treatments, cell viability was measured by MTT assay. Viable cell number relative to their vehicle controls for different treat-
ments is calculated. Each point is themean±SE of four independent experiments. Each samplewas counted in duplicate. (B and C) IGF-IR
expression was analyzed by immunoblot analysis followed by densitometry. (D) LNCaP and LNCaP/IGF-R cells were treated similarly as
described in A with 0.05, 0.1, 0.5, 1, 5, 10, and 50 μM lycopene for 72 hours. Cell viability is determined byMTT assays. The percentage of
cell viabilities relative to their vehicle controls for different treatments is calculated. Each point is the mean ± SE of four independent
experiments. Each sample was counted in duplicate.
112 Lycopene Supplementation Enhances Docetaxel’s Effect in Prostate Cancer Tang et al. Neoplasia Vol. 13, No. 2, 2011
Figure 3. PPP potentiates the growth-inhibitory effect of docetaxel on DU145 and LNCaP overexpressing IGF-IR cell lines. (A) LNCaP and
LNCaP/IGF-R cells were treated similarly as described above with 0.1%DMSO or 7.8, 15.6, 31.25, 62.5, 125, 250 or 500 nMPPP, a specific
IGF-IR kinase inhibitor for 72 hours. Cell viabilities are determined by MTT assays. The percentage of cell viabilities relative to their vehicle
controls for different treatments is calculated. Each point is themean± SE of four independent experiments. Each sample was counted in
duplicate. (B) DU145 and LNCaP/IGF-R cells were treated similarly as described abovewith 0.1%DMSO, 31.25 nMPPP, 1 nMdocetaxel, or
1 nM docetaxel plus 31.25 nM PPP for 72 hours. Cell viabilities are determined byMTT assays. The percentage of cell viabilities relative to
their vehicle controls for different treatments is calculated. Each point is the mean ± SE of four independent experiments. Each sample
was counted in duplicate. (C and D) DU145 Cells were treated with 0.1%DMSO, 31.25 nM PPP, 1 nM docetaxel, or 1 nM docetaxel (Doc1)
plus 31.25 nM PPP for 24 hours. Cells were stained by PI and pre-G1, and cell cycle populations were analyzed by flow cytometry. A rep-
resentative photograph of cell cycle population distribution for each treatment is presented. Bars represent the means from three inde-
pendent experiments. Standard errors are less than 5%.
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events of the IGF-IR signaling, AKT and survivin, will be more sub-
jected to the IGF-IR regulation in DU145 cells than in LNCaP cells.
Indeed, compared with their vehicle controls, 1 μM lycopene decreased
the levels of phospho-AKT in LNCaPandDU145 cells by approximately
20% and 60%, respectively. In addition, Figure 4A (panels g and h)
shows that LNCaP cells overexpressing IGF-IR have increased protein
levels of active AKTand antiapoptotic protein survivin compared with
the parental LNCaP cell line.
Figure 4C ( panels i and j) shows that docetaxel alone slightly increases
the protein expression of survivin, whereas docetaxel in combination
with lycopene or the IGF-IR kinase inhibitor, PPP, seems to synergis-
tically downregulate the protein expression of survivin in DU145 cells.
Figure 4. The effect of lycopene on IGF-IR and its mediated AKT/survivin pathway in PCa cells. (A) DU145 cells at 70% confluency were
serum-starved for 36 hours. During the last 2 hours of serum starvation, lycopene, PPP, and docetaxel at indicated concentrations were
added into the medium. After these treatments, cells were incubated with PBS or 100 ng/ml IGF-I for 15 minutes at 37°C. Cell lysates
were prepared, IGF-IR was immunoprecipitated using anti–IGF-IRβ antibody, and Western blot analyses were performed using anti-
phosphotyrosine (panel a) or anti–IGF-IRβ (panel b). Lanes 1, 2, 3, 4, 5, 6, and 7 denote vehicle control, vehicle control + 100 ng/ml IGF-I,
1 μMlycopene, 1μMlycopene+100 ng/ml IGF-I, 10μM lycopene+100 ng/ml IGF-I, 50 nMPPP+100ng/ml IGF-I, and 1 μMlycopene+1nM
docetaxel + 100 ng/ml IGF-I, respectively. Panel c: DU145 cells in the serummediumwere treated by lycopene at indicated concentrations
for 24 hours. IGF-BP3 expression in protein lysates was determined byWestern blot analysis. Panel d: DU145 in serum-free mediumwere
treated by lycopene at indicated concentrations for 48 hours. IGF-BP3 secretion was determined byWestern blot analysis of concentrated
conditioned medium. (B) LNCaP and DU145 cells were treated with 0.1% THF (vehicle control), 0.5, 1, or 10 μM lycopene for 24 hours.
Phospho-AKT and total AKT in the treated DU145, LNCaP, and LNCaP/IGF-IR cells were determined by Western blot analysis. DR denotes
densitometry measurement ratio relative to vehicle control. (C) DU 145 cells were treatedwith vehicle controls (0.1%DMSO, 0.1% THF, or
0.1% DMSO + 0.1% THF), 1 μM lycopene (lyco1), 10 μM lycopene (lyco10), 0.5 nM docetaxel (doc0.5), 1 nM docetaxel (doc1), 15.6 nM
PPP, 1 or 10 μM lycopene plus 1 nM docetaxel, or 15.6 nM PPP plus 1 nM docetaxel. DRs are densitometry ratios relative to vehicle con-
trols. (D) Graphical presentation of the proposed mechanisms of lycopene in inhibiting the IGF-IR–medicated survival pathway for the
enhancement of resistance to docetaxel-induced apoptosis.
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Taken together, these results suggest that lycopene inhibits IGF-IR
activation leading to inactivation of the AKT/survivin pathway.
Lycopene Supplement Enhances the Antitumor Efficacy of
Docetaxel and Prolongs the Survival of Tumor-Bearing
Mice in a Xenograft Model
Figure 5A shows that docetaxel and docetaxel-plus-lycopene treat-
ments result in a significant decrease in the growth rate of DU145 tu-
mors compared with vehicle control or 15mg/kg lycopene supplement
alone (ANOVA, P values < .05). The inhibitory effect of lycopene sup-
plement plus docetaxel on tumor growth is more pronounced than that
of docetaxel alone treatment (ANOVA, P values < .05). The tumor
weights of DU145 cells in control, docetaxel, lycopene, and docetaxel-
plus-lycopene groups recorded at the end of the treatment were 0.85 ±
0.36, 0.39 ± 0.24, 0.84 ± 0.28, and 0.15 ± 0.15 g (mean tumor weight ±
SD), respectively. Lycopene significantly enhanced the antitumor ef-
ficacy of docetaxel by approximately 38% (Student t test, P = .042;
Figure 5, B and C ).
The efficacy of lycopene supplement (15 mg/kg per day), docetaxel
(5 or 10 mg/kg per week for three doses), or combination of each was
further assessed using growth delay, measured as the time from the start
of tumor cell implantation for either tumor in amouse to reach a volume
of approximately 1500mm3 or when a mouse died spontaneously. Ad-
ministration of a higher dose of docetaxel (10mg/kg per week) or com-
bination of lycopene supplement with a lower (5 mg/kg per week)
or higher (10 mg/kg per week) dose of docetaxel prolonged the sur-
vival time ofmice (Figure 5D), compared with control, lycopene alone,
or low-dose docetaxel alone. The median times for tumors to reach
1500 mm3 in the control, lycopene supplement, and lower-dose doce-
taxel groups are 41.5 ± 6, 43 ± 7, and 45 ± 3 days, respectively. The
median times for tumors to reach 1500mm3 in the higher dose of doce-
taxel and combination of lycopene supplements with the high or low
dose of docetaxel groups are 62 ± 8, 64 ± 8, and 70 ± 4 days, respec-
tively, which demonstrated significantly delayed tumor growth by an
average of 21 to 32 days relative to the controls (Figure 5D; log-rank
tests, P values < .001). The efficacy of lycopene supplement in combi-
nation with the lower dose of docetaxel (5 mg/kg per week) to delay
tumor growth and prolonging the survival of tumor-bearing mice was
almost equal to that of the higher dose of docetaxel (10 mg/kg per
week) alone. These results confirm that lycopene supplementation en-
hanced the antitumor efficacy of docetaxel even at its suboptimal dose.
Lycopene Supplement and Docetaxel Combined Treatment
Induced a Significant Tumor Morphology Alternation
Resembling of Mitotic Catastrophe with Apoptosis,
as well as Decreased Cell Proliferation and
Survivin Expression in Tumor Tissues
Histologic analysis of hematoxylin and eosin–stained tumor sec-
tions from DU145 xenograft-bearing mice treated with lycopene
supplementation plus or minus docetaxel demonstrated a dramatic
change in tissue and cell morphology when compared with vehicle
control, lycopene supplement, or docetaxel alone (Figure 6A). These
changes include low cell density and multinucleated cells with con-
densed chromatin staining and pyknosis, indicating mitotic catastrophe
and apoptosis.
To examine whether these treatments affected cell proliferation and
apoptosis in in vivo situations, tumor xenograft tissue sections were
analyzed by immunohistochemistry for Ki67, a marker for cell prolif-
eration, and TUNEL, a marker for apoptotic response (Figure 6B). As
shown in Figure 6C , compared with controls, xenograft samples from
docetaxel alone and lycopene supplement-plus-docetaxel groups
showed a marked increase in number of TUNEL-positive cells. Quan-
titative evaluation of apoptosis showed that docetaxel (10 mg/kg per
week) alone and docetaxel-plus-lycopene supplement (15 mg/kg per
day) led 12.4% ± 3.2% and 24.6% ± 4.3% apoptotic cells, respec-
tively, compared with control or lycopene supplement alone showing
4.3% ± 1.2% or 5% ± 2.1% apoptotic cells (P values < .01). Docetaxel
plus lycopene supplement resulted in an increase in apoptotic cells
approximately 98% or 392% more than that of either docetaxel or
lycopene supplement alone (P values < .05). The quantification of
Ki67-positive cells in tumor sections showed no statistically significant
difference among the four different treatment groups (P values < .05).
Together, these results suggest that the enhancement of the antitumor
efficacy of docetaxel by lycopene supplement may be through mecha-
nisms of apoptosis induction.
These tumor sections were further stained with antisurvivin anti-
body. Figure 4G shows that tumor sections from mice treated with
lycopene alone or lycopene supplement in combination with docetaxel
demonstrated significantly less staining of survivin protein, whereas
docetaxel alone seemed to slightly increase the staining of survivin in
tumor sections.
Discussion
Lycopene has been suggested as a promising nutritional component for
the prevention and treatment of PCa [11,15]. As a result, many men
with PCa increase their intake of lycopene through dietary supplements
[28], although there are no large-scale trials to provide evidence-based
clinical practice guidelines [29–32]. In addition, docetaxel has recently
become the first-line chemotherapeutic regimen for CRPC patients. Be-
cause lycopene is a potent antioxidant, there is a concern whether lyco-
pene could protect tumor cells as well as the healthy cells from oxidative
damage generated by docetaxel-based chemotherapy and therefore at-
tenuate the antitumor efficacy of docetaxel [21]. In this study, our data
clearly demonstrate that lycopene supplementation can significantly en-
hance the antitumor efficacy of docetaxel in the regression of established
tumors in a CRPC xenograft model. This result should justify further
clinical investigation of potential benefits of lycopene and docetaxel
combinations for treatment of CRPC patients.
Several in vitro cell culture studies [33] have suggested that androgen-
induced increase in reactive oxygen species (ROS) levels in prostate
epithelial cells may play a key role in prostate cancer occurrence, recur-
rence, and progression. Therefore, agents that prevent the production
and chronic accumulation of ROS might be useful in the treatment of
prostate cancer. Venkateswaran et al. [34,35] reported that combina-
tions of antioxidants (i.e., lycopene, vitamin E, and selenium) resulted
in a significant reduction in both prostate cancer and liver metastasis in
the Lady transgenic mice, although the authors in this article did not
examine whether the anti–prostate cancer effects of these antioxidants
were due to their antioxidant properties. However, the authors did
show that a combination of vitamin E and selenium did not effectively
inhibit prostate cancer in the Lady transgenic mice. Consistently,
Limpens et al. [36] described that a lycopene and vitamin E combina-
tion reduced tumor growth and prostate-specific antigen plasma levels in
an orthotopic mouse model of human prostate cancer. Taken together,
these studies suggested that lycopene is necessary for the inhibitory ef-
fect of this combination on prostate cancer and that nonantioxidant
mechanisms are also involved in their antineoplastic actions. Because
there are concerns about the use of antioxidants during chemotherapy
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Figure 5. Lycopene supplementation improves the antitumor efficacy of docetaxel in the DU145 tumor xenograft model. DU145 cells
(1 × 106) were injected into the right flank of NCR-nu/nu (nude) mice. Once tumors started growing, their sizes were measured twice
weekly in two dimensions, throughout the study. The tumor volume was calculated by the formula: 0.5236L1(L2)
2, where L1 is the long
diameter and L2 is the short diameter. Tumor volume (mm
3) is represented as the mean of eight mice in each group. When tumor
volume reached 200 mm3 measured by caliper, mice bearing DU145 tumors were randomly divided into four or six different groups
as indicated. Control group of mice received water by gavage. Lycopene was given daily via gavage for the whole period, and docetaxel
was intraperitoneally injected into mice bearing DU145 tumors weekly for three doses. (A) Tumor growth curve, points, and mean tumor
volumes. Bars, SE. (B) Mean wet weights of tumors from different groups of treatments. At the termination of the study, tumors were
excised from each mouse in different groups and weighed. Bars, SE. (C) Photographs of tumors from different groups of treatments.
(D) Tumor growth curve for tumor volumes to reach 1500 mm3, points, mean tumor volumes. Bars, SE.
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Figure 6. Immunohistochemistry of DU145 tumors from mice treated with lycopene, docetaxel, or their combination. (A) Hematoxylin
and eosin staining of tumor sections from different treatment groups including vehicle control, lycopene (15 mg/kg per day), docetaxel
(10 mg/kg per week), and lycopene (15 mg/kg per day) plus docetaxel (10 mg/kg per week). Original magnification, ×200. (B) At the end of
the experiment, mice were killed, tumor tissues were analyzed for immunohistochemical staining of Ki67, and photomicrographs were
taken as described inMaterials andMethods. Proliferation indexwas calculated as the number of Ki67-positive cells × 100/total number of
cells counted under ×200 magnification in five randomly selected areas in each tumor sample. (C) Apoptotic cell population in tissues from
various groupswas analyzed by TUNEL assay as described inMaterials andMethods. Apoptotic indexwas calculated as the number of positive
cells × 100 / total number of cells counted under ×200 magnification in five randomly selected areas in each tumor sample. Mean ± SE from
eight mice in each group. (D) Immunostaining of survivin in tumor sections from the indicated treatment groups. Original magnification, ×200.
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[21], the ability of lycopene to inhibit cancer growth through non-
antioxidantmechanismsmay provide justification for combination ther-
apies involving this agent and cytotoxic drugs like docetaxel.
IGF-IR not only plays a role in prostate carcinogenesis [37,38] but also
is elevated in metastatic PCa and is associated with resistance to androgen
withdraw [17,18,39]. In addition, maintaining IGF-responsiveness
enables PCa survival and growth and is partially acquired through
androgen-regulated IGF-IR expression [28]. These results suggest that
IGF-IR is a critical target for prevention and treatment of CRPC. Ly-
copene has been shown to inhibit IGF-I signaling by down-regulation
of IGF-I expression and up-regulation of IGF-BPs [13,14,40,41]. In
this study, we showed that lycopene exhibited more potent inhibitory
effects on the growth of DU145 cells with higher expression levels of
IGF-IR than those PCa cell lines (e.g., LNCaP, 22Rv1, LAPC-4, PC-3)
with lower expression levels of IGF-IR. Moreover, transfected LNCaP
cells stably expressing high levels of IGF-IR were approximately 400-
fold more sensitive to lycopene than parental LNCaP cells (IC50 for
lycopene in LNCaP/IGF-IR was 0.08 μM vs an IC50 of 36 μM for
parental LNCaP cells). Intriguingly, although lycopene has been reported
to be accumulated in LNCaP cells to levels that are 4.5 times higher
than in DU145 cells [42], the growth-inhibitory effects of lycopene on
DU145 cells is approximately seven times more pronounced than that
on LNCaP cells (IC50 for DU145 vs LNCaP are 5.1 vs 36 μM). This
evidence indicates that IGF-IR levels may be more relevant to the
growth-inhibitory effect of lycopene on PCa cell lines than cellular
concentrations of lycopene. We hypothesized that lycopene existing
in extracellular or membrane compartments may also play a role on
IGF-IR activation. Our results confirmed that lycopene increased the
expression and secretion of IGF-BP3, which sequesters the IGF-IR
ligand. We also showed for the first time that lycopene treatment for
only 2 hours can inhibit IGF-I–induced IGF-IR phosphorylation in
DU145 cells. This result suggests a direct effect of lycopene on IGF-IR
activation. We also showed for the first time that lycopene can inhibit
IGF-I–induced IGF-IR phosphorylation in DU145 cells. Further studies
are in progress to determine whether lycopene can directly bind to IGF-I
or IGF-IR and then inhibit IGF-IR kinase activity.
The general mechanism of IGF-IR activation is to enhance survival
and protect cells from apoptosis [16]. In addition, the IGF-IR interacts
with, and influences, various signaling molecules such as ER, AR,
EGFR,HER-2, and the DNA damage response pathway [16]. Together,
these properties of IGF-IR activation provide mechanisms through
which it can cause resistance to multiple anticancer therapies including
chemotherapy, radiotherapy, and targeted therapies [16,25]. There-
fore, in general, anticancer therapies targeting the IGF axis are promis-
ing approaches for enhancing the efficacy of many conventional cancer
therapies, including docetaxel-based chemotherapy [43]. We show
here that the synergistic growth-inhibitory effect of lycopene and doce-
taxel was only found on those PCa cancer cell lines with higher IGF-IR
levels. This result provides a clue that CRPC patients with high levels
of IGF-IR activity may be most likely to benefit from combined ther-
apy with lycopene and docetaxel.
Multiple studies have demonstrated that docetaxel causes cell death
through mitotic catastrophe as well as through caspase-dependent and
-independent effects [44–46]. Our study showed that lycopene signifi-
cantly enhanced the apoptotic effect of docetaxel in PCa both in vitro
in cell cultures and in vivo in a xenograft model. The histologic analysis
of tumor tissue sections revealed that the combination of lycopene and
docetaxel resulted in a significant increase in the number of tumor cells
with abnormal DNA condensation and multinucleation, consistent
with mitotic catastrophe. Further study showed that the docetaxel
and lycopene combination could synergistically downregulate survivin
expression both in vitro and in vivo. Survivin is an antiapoptotic pro-
tein and plays a role in cell cycle regulation during mitosis [47]. Sur-
vivin inhibition, alone or in combination with the other therapies, has
been shown to induce or enhance apoptosis and mitotic catastrophe
in tumor cells [47]. In addition, survivin is regulated by IGFs and is
associated with the resistance to castration and progression in PCa
[47–49].On the basis of evidences described,we can argue that survivin,
serving as a critical downstream event for the combined effects of lyco-
pene and docetaxel, may be a useful biomarker for predicting the out-
come or response of this combined therapy in clinical studies.
In summary, these data provide a rationale for the clinical investi-
gation of the efficacy and safety profile of lycopene in combination
with docetaxel in CRPC patients. In particular, combining lycopene
with docetaxel may provide clinical benefit for men with metastatic
CRPC, for whom morbidity and mortality remain high despite wide
use of docetaxel chemotherapy. Themechanism of this combined ther-
apy seems to involve the IGF-IR/survivin pathway and is mediated by
mitotic catastrophe and apoptosis.
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